Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: risankizumab Clear all
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )

NCT03047395
View directory record Official record
Conditions
Psoriasis
Interventions
risankizumab
Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
2,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
79
States / cities
Birmingham, Alabama • Rogers, Arkansas • Bakersfield, California + 65 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 3 Interventional Results available

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

NCT04435600
View directory record Official record
Conditions
Psoriasis
Interventions
Risankizumab, Ustekinumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
21
States / cities
Birmingham, Alabama • Fountain Valley, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

NCT05969223
View directory record Official record
Conditions
Genital Psoriasis, Scalp Psoriasis
Interventions
Risankizumab, Placebo for Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 25, 2026, 10:58 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05995353
View directory record Official record
Conditions
Crohn's Disease
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
11
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Oakland, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants

NCT06937619
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
4
States / cities
Anaheim, California • Los Alamitos, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 4 Interventional

A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

NCT06333860
View directory record Official record
Conditions
Moderate Plaque Psoriasis
Interventions
Risankizumab, Deucravacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
39
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 25, 2026, 10:58 PM EDT
Recruiting No phase listed Observational

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

NCT04846959
View directory record Official record
Conditions
Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment
Interventions
Risankizumab, Comparator
Drug
Lead sponsor
AbbVie
Industry
Eligibility
Female only
Enrollment
818 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
2
States / cities
Morrisville, North Carolina • Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 25, 2026, 10:58 PM EDT
Active, not recruiting No phase listed Observational

VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

NCT06249555
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab (VDZ), Ustekinumab (UST), Risankizumab (RISA), Guselkumab (GUS), Mirikizumab (MIR)
Drug
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Sun City, Arizona • Evanston, Illinois • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 3 Interventional Results available

Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

NCT04713592
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo for Risankizumab, Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
34
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Sep 25, 2026, 10:58 PM EDT
Recruiting Phase 3 Interventional

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

NCT07499232
View directory record Official record
Conditions
Crohn Disease
Interventions
Guselkumab, Risankizumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
39
States / cities
Dothan, Alabama • Mobile, Alabama • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 25, 2026, 10:58 PM EDT
Active, not recruiting Phase 3 Interventional

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT04524611
View directory record Official record
Conditions
Crohn's Disease (CD)
Interventions
Risankizumab, Ustekinumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
72
States / cities
Chandler, Arizona • Coronado, California • Irvine, California + 62 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 25, 2026, 10:58 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Risankizumab, Vedolizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
74
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 65 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 25, 2026, 10:58 PM EDT
Recruiting Phase 2 Interventional

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

NCT06548542
View directory record Official record
Conditions
Crohn's Disease
Interventions
Risankizumab, Lutikizumab, Trosunilimab, ABBV-8736
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
64
States / cities
Dothan, Alabama • Mobile, Alabama • Coronado, California + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 25, 2026, 10:58 PM EDT
Recruiting Phase 2 Interventional

Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

NCT06865105
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Lutikizumab, Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
16
States / cities
Huntington Beach, California • Avon Park, Florida • Clearwater, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers

NCT05274087
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 25, 2026, 10:58 PM EDT
Recruiting Not applicable Interventional

Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors

NCT06399432
View directory record Official record
Conditions
Psoriasis
Interventions
Mediterranean Diet
Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 94 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 25, 2026, 10:58 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants

NCT07466550
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Anaheim, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers.

NCT05567029
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Risankizumab Dose A, Risankizumab Dose B
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
5
States / cities
Anaheim, California • Miami, Florida • Grayslake, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 1 Interventional

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

NCT01577550
View directory record Official record
Conditions
Psoriasis
Interventions
BI 655066 (very high i.v. dose), Placebo, i.v., BI 655066 (high s.c. dose), BI 655066 (low i.v. dose), BI 655066 (high medium i.v. dose), BI 655066 (very low i.v. dose), BI 655066 (low s.c. dose), BI 655066 (high i.v. dose), Placebo, s.c., BI 655066 (low medium i.v. dose)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Burbank, California • Miami, Florida • Port Orange, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants

NCT06571266
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Anaheim, California • Los Alamitos, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

NCT06624228
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab, Risankizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants

NCT05274100
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
8
States / cities
Anaheim, California • Cypress, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 25, 2026, 10:58 PM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 25, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab

NCT05305222
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Risankizumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 25, 2026, 10:58 PM EDT